Philip Arlen
Overview
Explore the profile of Philip Arlen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huffman B, Basu Mallick A, Horick N, Wang-Gillam A, Hosein P, Morse M, et al.
JAMA Netw Open
. 2023 Jan;
6(1):e2249720.
PMID: 36602796
Importance: Treatment options are limited for patients with advanced pancreatic ductal adenocarcinoma (PDAC) beyond first-line 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX), with such individuals commonly being treated with gemcitabine and...
2.
Arlen M, Arlen P, Coppa G, Crawford J, Wang X, Saric O, et al.
World J Gastrointest Oncol
. 2014 Jun;
6(6):170-6.
PMID: 24936227
In an attempt to improve upon the end results obtained in treating colorectal cancer it was apparent that the earlier the diagnosis that could be obtained, the better the chance...
3.
Arlen M, Arlen P
J Cancer
. 2013 Jul;
4(5):427-32.
PMID: 23833687
In a recent issue of Nature, an article appeared discussing the issue of "Sizing up a slow assault on Cancer" (Nature 2013;496:14-15). This article attempted to clarify various approaches that...
4.
Arlen M, Saric O, Wang X, Dubeykovskiy A, Arlen P
J Cancer
. 2013 Feb;
4(2):165-9.
PMID: 23412851
The ability to define malignancy in its earliest stages of development is an essential part of any program aimed at attempting to cure the malignant condition. In terms of colon...
5.
Arlen M, Arlen P, Tsang A, Wang X, Gupta R
J Cancer
. 2010 Nov;
1:209-22.
PMID: 21060731
Monoclonal antibodies developed against immunogenic proteins (Tumor Specific Antigens/TSA's) that are expressed in human cancers, display a unique behavioral pattern. They appear to serve in a dual role. This includes...
6.
Hryniewicz A, Price D, Moniuszko M, Boasso A, Edghill-Spano Y, West S, et al.
J Immunol
. 2007 Mar;
178(6):3492-504.
PMID: 17339444
The loss of CD4(+) T cells and the impairment of CD8(+) T cell function in HIV infection suggest that pharmacological treatment with IL-7 and IL-15, cytokines that increase the homeostatic...
7.
Sharifi N, Dahut W, Steinberg S, Figg W, Tarassoff C, Arlen P, et al.
BJU Int
. 2005 Oct;
96(7):985-9.
PMID: 16225513
Objective: To determine the natural history of patients with prostate cancer who start initial androgen-deprivation therapy (ADT) for biochemical failure with no radiographic evidence of disease (D0) or with radiographic...
8.
Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, Pastan I, et al.
Clin Cancer Res
. 2005 Sep;
11(17):6342-51.
PMID: 16144939
Purpose: Mesothelin is overexpressed in many pancreatic and ovarian cancers, mesotheliomas, and other tumor types. Clinical trials are ongoing using immunotoxins to target mesothelin, and patients immunized with allogeneic pancreatic...
9.
Figg W, Liu Y, Arlen P, Gulley J, Steinberg S, Liewehr D, et al.
J Urol
. 2005 Feb;
173(3):790-6.
PMID: 15711271
Purpose: Alendronate (AL), a potent oral bisphosphonate, blocks the secretion of matrix metalloproteinase-2 and the establishment of bone metastases in animal models. Ketoconazole (KT) has demonstrated activity in androgen independent...
10.
Tsang K, Palena C, Gulley J, Arlen P, Schlom J
Clin Cancer Res
. 2004 Mar;
10(6):2139-49.
PMID: 15041735
Purpose: MUC-1/DF-3 remains an attractive target for vaccine therapy. It is overexpressed in the majority of human carcinomas and multiple myeloma. Clinical trials using MUC-1-based vaccines have demonstrated safety, clinical...